1. Discovery of N-phenyl-1-(phenylsulfonamido)cyclopropane-1-carboxamide analogs as NLRP3 inflammasome inhibitors
- Author
-
Long Tai Zheng, Wanwan Li, Zhongqiang Cao, Na Ye, Junjie Cheng, Feiyu Chen, Shuai Li, and Yiwei Huang
- Subjects
Sulfonyl ,chemistry.chemical_classification ,010405 organic chemistry ,Stereochemistry ,medicine.drug_class ,Organic Chemistry ,Inflammasome ,Carboxamide ,01 natural sciences ,Sulfonylurea ,0104 chemical sciences ,Cyclopropane ,010404 medicinal & biomolecular chemistry ,chemistry.chemical_compound ,chemistry ,medicine ,Bioorganic chemistry ,General Pharmacology, Toxicology and Pharmaceutics ,Cytotoxicity ,Linker ,medicine.drug - Abstract
Two series of novel NLRP3 inflammasome inhibitors are designed, synthesized, and evaluated in an effort to develop diversified analogs based on the N-(phenylcarbamoyl)benzenesulfonamide scaffold. SAR studies reveal that the sulfonylurea linker can tolerate chemical modifications with either simply changing over the position of carbonyl and sulfonyl group or structurally flexibly inserting a cyclopropyl group, leading to identification of several more potent and diversified NLRP3 antagonists (e.g., 9) with low nanomolar inhibitory activities. Further studies indicate that these two series of compounds with low cytotoxicity exhibited weak effects on the generation of NO and TNF-a. The findings may serve as good starting points for the development of more potent NLRP3 inflammasome inhibitors as valuable pharmacological probes or potential drug candidates.
- Published
- 2021
- Full Text
- View/download PDF